勃林格殷格翰的思力华哪里有售？

The main ingredient of Respimat is tiotropium bromide, which has an affinity similar to the muscarinic receptor subtype MI-M5. It can bind to the M3 receptor on smooth muscle, block the efferent branch of the postganglionic vagus nerve, relax the smooth muscle to achieve the purpose of dilating the bronchus, and can also reduce the bronchial airway inflammatory response and delay the further development of lung function. Based on the results of previous clinical trials, Silihua has significant clinical efficacy in treating stable chronic obstructive pulmonary disease, can significantly improve patients' pulmonary function indicators, and has few adverse reactions, making it worthy of vigorous clinical promotion and application. So, where can Boehringer Ingelheim’s Spiriva be sold?

Siliva was launched globally in 2002, and in 2006 it was launched in China. In 2007, the Respimat device was launched globally. In these listed countries and regions, patients can buy Spiriva from Boehringer Ingelheim of Germany. For domestic patients, they can also enjoy the discounts brought by medical insurance when purchasing medicines in major domestic hospitals and pharmacies. However, despite this, many patients with poor family finances still cannot afford the costs of long-term treatment. In this regard, patients can purchase medicines overseas through Medical Companion Travel, where they can buy more cost-effective Silivar.

Boehringer Ingelheim is the largest and most successful privately held pharmaceutical group in the world and has successfully ranked among the top 20 pharmaceutical companies in the world. Boehringer Ingelheim's first office in my country was established as early as March 1994, and it took only about 14 months to officially register the first Chinese branch called Boehringer Ingelheim International Trading (Shanghai) Co., Ltd. in Waigaoqiao, Shanghai.

So far, Boehringer Ingelheim's sales business covers eight regions across the country, mainly concentrated in major provinces and cities, centered on Shenyang, Beijing, Hangzhou, Nanjing, and Shanghai. Boehringer Ingelheim continues to inject new products into the Chinese market, including drugs for the treatment of chronic obstructive pulmonary disease (COPD).

Recommended hot articles: /newsDetail/92332.html